Effects of Paroxetine on Cardiovascular Function in Septic Patients
Septic Shock, Sepsis
About this trial
This is an interventional treatment trial for Septic Shock
Eligibility Criteria
Inclusion Criteria: Patient over 18 years of age; Patient diagnosed with septic shock for less than 48 hours and using a minimum dose of noradrenaline (0.01 mcg/kg/min); Patients and/or legal guardians who consented to participate in the study through the free and informed consent term before randomization. Exclusion Criteria: Pregnant women; Patients with inability to use the gastrointestinal tract; Patients with known intolerance to paroxetine and/or fluoxetine; Patients on concomitant use of medications that may potentiate the occurrence of serotonin syndrome (tramadol, citalopram, escitalopram, sertraline, desvenlafaxine, venlafaxine, duloxetine, sibutramine, bupropion, amitriptyline, nortriptyline, lithium); Patients in end-of-life care or with an expected survival of less than 24 hours at the time of eligibility
Sites / Locations
- Hospital Maternidade São José de ColatinaRecruiting
- Hospital São JoséRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Sham Comparator
Experimental
Placebo
Fluoxetine
Paroxetine
40mg, single dose a day, by mouth or enteric tube
Fluoxetine, as paroxetine, has activity upon serotonin uptake, but not on GRK-2 40mg, single dose a day, by mouth or enteric tube
40mg, single dose a day, by mouth or enteric tube